Got 90 Seconds? Then listen to Volpara’s executive director and CEO talk about their recent wins and what is next for the medical technology company.

Volpara Health Technologies (ASX:VHT) is a medtech company on a mission to improve the early detection of breast cancer.

Its core product, the Volpara Density software, is an automated breast density solution available to customer clinics.

Breast density data can help clinicians make more informed decisions about breast cancer risk.

This month, Volpara reported an 86 per cent increase in recurring revenues for FY 2019.

The company has also been expanding its US operations with 7 per cent of US women being screened now analysed by Volpara.

Stockhead spoke to Volpara’s executive director and CEO Ralph Highnam at last week’s Microcaps Conference in Sydney.

Have a good idea for our next 90 Seconds With segment? Email us at tv@stockhead.com.au.